Form 4: 10x Genomics Director Sells Shares
Insider Transaction (Form 4)
John R Stuelpnagel, a Director of 10x Genomics, Inc., sold 20,000 shares of common stock on September 3, 2026.
Summary
- Open-market sale: disposed of 7,012 Class A Common Stock at $60.66 ($425,333) on September 3, 2026; holds 341,424 after (Direct).
- Open-market sale: disposed of 6,814 Class A Common Stock at $62.11 ($423,205) on September 3, 2026; holds 334,610 after (Direct).
- Open-market sale: disposed of 6,174 Class A Common Stock at $62.61 ($386,533) on September 3, 2026; holds 328,436 after (Direct).
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $1,235,072 of stock on the open market.
Insider Transactions
John R Stuelpnagel — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-03 | Open-market sale | Class A Common Stock | 7,012 | $61 | $425.3K | 341,424 |
| 2026-09-03 | Open-market sale | Class A Common Stock | 6,814 | $62 | $423.2K | 334,610 |
| 2026-09-03 | Open-market sale | Class A Common Stock | 6,174 | $63 | $386.5K | 328,436 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-03 | Open-market sale (7,012 shares) |
| 2026-09-03 | Open-market sale (6,814 shares) |
| 2026-09-03 | Open-market sale (6,174 shares) |
Keywords
insider transaction, Form 4, TXG, 10x Genomics, Inc., bearish, John R Stuelpnagel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.